financetom
Business
financetom
/
Business
/
What's Going On With Chinese EV-Maker Nio's Stock?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Chinese EV-Maker Nio's Stock?
Apr 12, 2024 8:36 AM

Nio, Inc. ( NIO ) shares are trading lower Friday after Ohio Senator Sherrod Brown called for a ban on imports of China-made EVs to the US. 

The Details:

Senator Brown sent a letter to President Biden on Thursday, urging him to ban the sale of Chinese EVs in the United States. 

"Chinese EVs, highly subsidized by the Chinese government, could decimate our domestic automakers, harm American workers – many of whom are represented by the United Autoworkers (UAW) – and give China access to sensitive personal data," Senator Brown wrote in the letter. 

The Senator's call for a ban on Chinese EVs follows Treasury Secretary Janet Yellen's trip to China where she spoke with government officials regarding government subsidies and other trade practices. The talks were reportedly intensive and ongoing. 

Related News: Treasury Secretary Janet Yellen Sees ‘Flood Of Chinese Exports Wiping Out’ US Green Energy Industry

Is NIO A Good Stock To Buy?

Wall Street analysts view Nio on the whole as a Neutral, given the history of coverage over the past three months. Nick Lai from JP Morgan is the most bearish, expecting a 41.18% fall in the stock in the coming year.

Looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past 3 months, Nio fell 40.7%, which indicates that opinion soured on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 3.43% over the past year.

A complete overview of how Wall Street views individual stocks is available here, while real time updates on the latest analyst actions will be delivered via Benzinga PRO. Try it for free.

NIO Price Action: According to Benzinga Pro, Nio shares are down 7.17% at $4.14 at the time of publication Friday. 

Image from Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Freegold Ventures Announced Additional Results From the 2024 Drilling Program
Freegold Ventures Announced Additional Results From the 2024 Drilling Program
Oct 10, 2024
07:43 AM EDT, 10/08/2024 (MT Newswires) -- Freegold Ventures Limited ( FGOVF ) on Tuesday announced additional results from the 2024 drilling program. In a statement Freegold ( FGOVF ) said 27 holes have been completed, with two more currently in progress. It noted the 2024 drill program is strategically targeting the western extension for potential additional expansion ahead of...
Siga Technologies to supply mpox therapy in Morocco
Siga Technologies to supply mpox therapy in Morocco
Oct 10, 2024
Oct 8 (Reuters) - Drugmaker Siga Technologies said on Tuesday it would supply its therapy for mpox in Morocco, in response to a request from the country's health ministry for protection against any potential outbreak of the disease. ...
Southwest Airlines Pick of the Week at Smart Insider Following Stock Purchases by Director, Executive Chair
Southwest Airlines Pick of the Week at Smart Insider Following Stock Purchases by Director, Executive Chair
Oct 10, 2024
07:41 AM EDT, 10/08/2024 (MT Newswires) -- Southwest Airlines ( LUV ) was the stock pick of the week from Smart Insider after the company's Director Rakesh Gangwal bought $107 million worth of shares at $29.64 apiece from Sept. 30 to Oct. 1. While new to the board it is encouraging to see him make such a large investment, Smart...
Merck's Keytruda Meets Primary Endpoint in Late-Stage Head and Neck Cancer Trial
Merck's Keytruda Meets Primary Endpoint in Late-Stage Head and Neck Cancer Trial
Oct 10, 2024
07:44 AM EDT, 10/08/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday that its Keytruda treatment met the primary endpoint of event-free survival in the late-stage Keynote-689 trial for patients with stage III or IVA resected, locally advanced head and neck squamous cell carcinoma. Merck ( MRK ) said the trial evaluated Keytruda as perioperative treatment before surgery and...
Copyright 2023-2025 - www.financetom.com All Rights Reserved